Table 1. Baseline characteristics.
| Characteristics | n (%)/mean ± SD |
|---|---|
| Gender | |
| Male | 25 (83.3) |
| Female | 5 (16.7) |
| Age (years) | 58.5±9.1 |
| Etiology | |
| Hepatitis B | 24 (80.0) |
| Hepatitis C | 4 (13.3) |
| Unknown | 2 (6.7) |
| BCLC stage | |
| A | 0 (0.0) |
| B | 12 (40.0) |
| C | 18 (60.0) |
| AST (U/L) | 37.9±18.3 |
| ALT (U/L) | 30.9±22.1 |
| PLT (×109) | 139.7±99.1 |
| TB (μmol/L) | 16.6±7.1 |
| ALB (g/L) | 38.0±5.6 |
| PT (s) | 20.1±18.5 |
| AFP (μg/L) | 4,810.0±12,421.5 |
| Macrovascular invasion | 12 (40.0) |
| Extrahepatic metastasis | 13 (13.3) |
| Lung | 7 (23.3) |
| Retroperitoneal lymph node | 5 (16.7) |
| Bone | 2 (6.7) |
| Paranephros | 2 (6.7) |
| Pleura | 1 (3.3) |
| Brain | 1 (3.3) |
| Initial dose of lenvatinib | |
| 12 mg | 14 (46.7) |
| 8 mg | 16 (53.3) |
| Reduced initial dose of lenvatinib | 7 (23.3) |
Measurement data is presented as mean ± SD; count date is presented as numbers and percentages. SD, standard deviation; BCLC stage, Barcelona Clinic Liver Cancer stage; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PLT, platelet; TB, total bilirubin; ALB albumin; PT, prothrombin time; AFP, alpha-fetoprotein.